Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Unilever plc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Unilever plc trades at $65 (market cap $134.00B). The key difference: Unilever plc is far larger — about 15.1× Kymera Therapeutics Inc. Common Stock's market cap, and Unilever plc pays a 3.4% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Unilever plc for 112 Days on average.
| KYMR | UL | |
|---|---|---|
Market Cap | $8.87B | $134.00B |
Volume | 779,107 | 2,393,833 |
Sector | Health | Consumer Staples |
52-Week High | $127.31 | $74.59 |
52-Week Low | $55.80 | $55.05 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $8.26B | $158.93B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Unilever (UL) trades at $63.86, up 1.45% on the day, with a bullish technical signal and strong profitability metrics including a 18.32% net income margin and 54.56% ROE. Recent earnings have consistently missed expectations, but the company is undergoing strategic portfolio streamlining, including a planned $65 billion food business merger with McCormick, which is under regulatory scrutiny. Cash flow from operations remains robust at $8.35 billion for 2025, though net cash flow was negative $2.08 billion due to significant investing and financing outflows.
The outlook is mixed: analyst consensus is a 'Hold' with a $66.08 price target, suggesting modest upside, but risks include execution of the McCormick deal, competitive pressures, and recent earnings misses. The stock's valuation at a P/E of 21.87 appears reasonable given its defensive emerging market exposure and high margins, but investor sentiment is cautious pending clearer signs of sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
